AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product.
FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.